IntroductionFor patients with corticosteroid (CS)-refractory immune checkpoint inhibitor–related cholangiohepatitis (irCH), no consensus exists regarding treatment, and outcomes remain poor. We evaluated the possibility of personalized treatment according to patient’s cytokine profile immunohistopathologic assessment predominant infiltrate type liver tissue.MethodsNSCLCs CS-refractory irCH were...